IRLAB launches new website

IRLAB announced today that a new website, www.irlab.se, has been launched. The new website provides the market with clearer information about IRLAB and its operations. This is one of several preparatory activities that IRLAB carries out ahead of the planned move to the Nasdaq Stockholm Main Market during 2020.

Nicholas Waters, CEO at IRLAB, commented “We launch a new website with new technical functionality and broadened information about our business and the drug development projects the company is running. Our goal during 2020 is to apply for and list the company’s share on the Nasdaq Stockholm Main Market. Both the launch of the website and the share issue the company carries out during February are important steps in this process.”

IRLAB was listed on the Nasdaq Stockholm Premier Growth Market on February 28, 2017.

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and IRL752, both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, info@fnca.se, +46 (0)8528 00 399. More information on www.irlab.se.